5-Methyl-4,5,6,7-tetrahydrobenzimidazol | 26663-91-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-Methyl-4,5,6,7-tetrahydrobenzimidazol
• 英文别名: 5-methyl-4,5,6,7-tetrahydro-1(3)H-benzoimidazole；5-Methyl-4,5,6,7-tetrahydro-1(3)H-benzimidazol；5-methyl-4,5,6,7-tetrahydro-1H-1,3-benzodiazole；6-methyl-4,5,6,7-tetrahydro-1H-benzimidazole
• CAS: 26663-91-2；76748-88-4
• 化学式: C₈H₁₂N₂
• 分子量: 136.197
• InChiKey: PWZQQGFNXZFVEZ-UHFFFAOYSA-N

物化性质

• 沸点：
  325.2±11.0 °C(Predicted)
• 密度：
  1.065±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 2-hydroxy-4-methylcyclohexanone 在 ammonium hydroxide 、 sodium hydroxide 、 乙醇 、 copper diacetate 作用下， 生成 5-Methyl-4,5,6,7-tetrahydrobenzimidazol
  参考文献：
  名称：

  Weidenhagen; Wegner, Chemische Berichte, 1938, vol. 71, p. 2124,2128

  摘要：

  DOI：

文献信息

• [EN] INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE<br/>[FR] INHIBITEURS DE LA KINASE ASSOCIÉE AU RÉCEPTEUR DE L'INTERLEUKINE-1
  申请人：PHARMACYCLICS LLC

  公开号：WO2017205766A1

  公开（公告）日：2017-11-30

  Disclosed herein are inhibitors of IRAK protein kinase of formula (I). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the IRAK inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了一种化学式（I）的IRAK蛋白激酶抑制剂。还披露了包含这些化合物的药物组合物。描述了使用这些IRAK抑制剂的方法，单独或与其他治疗剂合并使用，用于治疗自身免疫性疾病或症状、异源免疫性疾病或症状、癌症（包括淋巴瘤）和炎症性疾病或症状。
• [EN] INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE<br/>[FR] INHIBITEURS DE LA KINASE ASSOCIÉE AU RÉCEPTEUR DE L'INTERLEUKINE 1
  申请人：PHARMACYCLICS LLC

  公开号：WO2017205762A1

  公开（公告）日：2017-11-30

  Disclosed herein are inhibitors of IRAK protein kinase. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the IRAK inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文揭示了抑制IRAK蛋白激酶的抑制剂。还揭示了包括这些化合物的制药组合物。描述了使用IRAK抑制剂的方法，单独或与其他治疗剂联合使用，用于治疗自身免疫性疾病或病况、异种免疫性疾病或病况、癌症（包括淋巴瘤）和炎症性疾病或病况。
• TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Babu Srinivasan

  公开号：US20110201593A1

  公开（公告）日：2011-08-18

  The invention provides novel compounds of formula I having the general formula: wherein R 1 , R 2 , R 3 , X and Y are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.

  本发明提供了具有以下一般式的新化合物I： 其中R1、R2、R3、X和Y如本文所述。因此，这些化合物可以在药学上可接受的组合物中提供，并用于治疗免疫或过度增生性疾病。
• CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1
  申请人：Eli Lilly & Company

  公开号：EP2029576B1

  公开（公告）日：2013-06-19
• METHODS AND COMPOSITIONS FOR DELIVERING 5-HT3 ANTAGONISTS ACROSS THE ORAL MUCOSA
  申请人：SINGH NIKHILESH N.

  公开号：US20100256210A1

  公开（公告）日：2010-10-07

  Methods for treating a patient with ondansetron are described. The method includes administering a solid pharmaceutical composition having ondansetron and a buffer to the patient. Ondansetron is absorbed across a permeable membrane of the patient's oral mucosa. The buffer may include two different buffering agents, such as sodium carbonate and sodium bicarbonate. The buffer may raise the pH of saliva to a pH of between 7.1 to 13. The patient may suffer from emesis, such as nausea and vomiting associated with cancer chemotherapy and radiotherapy.